

**Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy, UNC**  
Departments of Medicine and Genetics, February 2007 to Present

**A Phase III, Randomized, Multicenter, Double-Blind, Parallel-Group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etxilate (150 mg bid) Compared to Warfarin (INR 2.0 - 3.0) for the Secondary Prevention of Venous Thromboembolism, UNC Hospitals,**  
February 2007 to Present

**A Phase III, Randomized, Double-Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etxilate (150 mg bid) Compared to Warfarin (INR 2.0-3.0)for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 days), UNC Hospitals, February 2007 to Present**

**Patient Time Requirements for Anticoagulation, UNC Department of Medicine, January 2007 to November 2007**